Abstract
A mass immunization campaign was conducted in the Province of Quebec, Canada, during the winter of 1993, following an increase in the incidence of meningococcal disease, which was mainly caused by a virulent clone of Neisseria meningitidis, serogroup C, serotype 2a. About 1.6 million doses of the polysaccharide vaccine were administered, covering 84% of the target population aged between 6 months and 20 years; the overall cost was about 25.5 million Canadian dollars. Cases notified to the regional health authorities by clinicians, hospital laboratories, and the provincial reference laboratory from January 1990 up to March 1994 have been included in the analysis. In the first year following the campaign, the incidence of the disease dropped markedly among vaccinees as well as the unvaccinated fraction of the target population, while it remained unchanged among persons aged more than 20 years. This suggests the existence of herd immunity. The overall field efficacy of the vaccine was 79%, more in teenagers and less in under-5-year-olds. A minimum of 37 cases were prevented during the first year.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ashton F. E., Ryan J. A., Borczyk A., Caugant D. A., Mancino L., Huang D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol. 1991 Nov;29(11):2489–2493. doi: 10.1128/jcm.29.11.2489-2493.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Devine L. F., Pierce W. E., Floyd T. M., Rhode S. L., Edwards E. A., Siess E. E., Peckinpaugh R. O. Evaluation of group C meningococcal polysaccharide vaccine in marine recruits, San Diego, California. Am J Epidemiol. 1970 Jul;92(1):25–32. doi: 10.1093/oxfordjournals.aje.a121176. [DOI] [PubMed] [Google Scholar]
- Gold R., Artenstein M. S. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ. 1971;45(3):279–282. [PMC free article] [PubMed] [Google Scholar]
- Gotschlich E. C., Goldschneider I., Artenstein M. S. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med. 1969 Jun 1;129(6):1385–1395. doi: 10.1084/jem.129.6.1385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gotschlich E. C., Goldschneider I., Artenstein M. S. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med. 1969 Jun 1;129(6):1385–1395. doi: 10.1084/jem.129.6.1385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jackson L. A., Schuchat A., Reeves M. W., Wenger J. D. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA. 1995 Feb 1;273(5):383–389. [PubMed] [Google Scholar]
- Longini I. M., Jr, Halloran M. E., Haber M., Chen R. T. Measuring vaccine efficacy from epidemics of acute infectious agents. Stat Med. 1993 Feb;12(3-4):249–263. doi: 10.1002/sim.4780120309. [DOI] [PubMed] [Google Scholar]
- Whalen C. M., Hockin J. C., Ryan A., Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA. 1995 Feb 1;273(5):390–394. [PubMed] [Google Scholar]
- Yergeau A., Alain L., Pless R., Robert Y. Adverse events temporally associated with meningococcal vaccines. CMAJ. 1996 Feb 15;154(4):503–507. [PMC free article] [PubMed] [Google Scholar]